Prognostic value of pretreatment serum levels of lactate dehydrogenase in nonmetastatic nasopharyngeal carcinoma: single-site analysis of 601 patients in a highly endemic area

Abstract

BackgroundNumerous studies have generated promising but incomplete evidence for the prognostic value of pretreatment serum levels of lactate dehydrogenase (S-LDH) in nasopharyngeal carcinoma (NPC).MethodsPretreatment serum levels of S-LDH in 601 patients with NPC were measured before treatment, and their associations with overall survival and tumor-free survival were studied. Univariate and multivariate analysis of subgroups was used to evaluate the prognostic value of S-LDH in early-stage and late-stage NPC separately.ResultsPretreatment S-LDH levels were significantly lower in T1+2 patients than in T3+4 patients, lower in N0+1 patients than in N2+3 ones, and lower in stage I + II patients than in III + IV ones. Multivariate analysis showed that among patients with late-stage NPC, high pretreatment S-LDH levels >225 U/L were an independent predictor of poor overall survival and tumor-free survival. Among patients with early-stage NPC, pretreatment S-LDH levels >171 U/L, which overlap with the normal range, were an independent predictor of shorter overall survival and tumor-free survival.ConclusionPretreatment S-LDH levels may be a reliable biomarker for predicting the long-term prognosis of patients with early-stage or late-stage NPC.

Pre-treatment serum alkaline phosphatase and lactate dehydrogenase as prognostic factors in triple negative breast cancer

“…High ALP level was reported to be related with worse prognosis in colorectal cancer 7, nasopharyngeal carcinoma 8, prostate cancer9, and esophageal squamous cell carcinoma10. Serum LDH level was demonstrated to be a prognostic factor in nasopharyngeal carcinoma11, lymphoma12, small cell lung cancer13, myeloma14 and prostate cancer15. However, the prognosis value of serum ALP and LDH in TNBC has remained unclear.…”

The prognostic value of plasma soluble CD40 ligand levels in patients with nasopharyngeal carcinoma

“…All variables were expressed as the number or mean ± standard deviation, unless otherwise stated. In addition, according to some other papers [36][37][38][39], age was bifurcated to ≥ 50 years and b 50 years. Chi-square tests and t test were performed for intergroup comparisons.…”

Prognostic Value of Pretreatment Serum Alkaline Phosphatase in Nasopharyngeal Carcinoma

“…This study was approved by the Ethics Committee of Guangxi Medical University. The patients analyzed have been studied in previous work examining the association between lactate dehydrogenase levels and prognosis (Wei et al, 2014). The inclusion criteria for patients in this study were as follows: (a) histological diagnosis with type II or III NPC based on the World Health Organization typing system; (b) analysis of the nasopharynx and head and neck using computed tomography or magnetic resonance imaging before radical treatment; (c) no radiotherapy or chemotherapy before collection of blood for S-ALP measurements; (d) no evidence of distant metastasis or secondary carcinoma at diagnosis; (e) complete radical radiotherapy, with or without chemotherapy; and (f) absence of serious heart, lung, kidney, liver and bone problems that would disqualify patients from receiving radiotherapy and chemotherapy.…”